Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2001-12-20

Original market date: See footnote 1

2001-12-20

Product name:

FLOVENT HFA

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section .

DIN:

02244291

Product Monograph/Veterinary Labelling:

Date: 2021-03-01 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company: 

GLAXOSMITHKLINE INC
7333 Mississauga Road
Mississauga
Ontario
Canada  L5N 6L4

Class: 

Human

Dosage form(s):

Metered-Dose Aerosol

Route(s) of administration:

Inhalation,  Oral

Number of active ingredient(s):

1

Schedule(s):

Prescription  

Biosimilar Biologic Drug:

No

American Hospital Formulary Service (AHFS): See footnote 3

68:04.00   ADRENALS

Anatomical Therapeutic Chemical (ATC): See footnote 4

R03BA05  FLUTICASONE

Active ingredient group (AIG) number:See footnote 5

0124685001

List of active ingredient(s)
Active ingredient(s) Strength
FLUTICASONE PROPIONATE 50 MCG / ACT

Application information

Related information

Contact us

Version 3.8.0
Date modified: